India's drug regulator, central drugs standard control organisation (CDSCO), has prohibited all direct and indirect promotional activities for glucagon-like peptide-1 (GLP-1) receptor agonist drugs, including celebrity-fronted obesity awareness campaigns, warning that surrogate advertising of prescription-only weight-loss medicines will be treated as a regulatory violation. All this at a time when Ozempic is preparing to go off-patent and over 30 generic versions are preparing to flood the Indian market.
CDSCO has issued a strict advisory prohibiting all manufacturers, importers, and marketing authorisation holders of GLP-1 receptor agonist drugs from engaging in any form of promotional activity, direct or indirect, for their prescription-only weight-loss and diabetes medicines, targeting what it described as a pattern of surrogate advertising disguised as disease awareness campaigns.
The advisory arrives at a particularly charged moment: Novo Nordisk's blockbuster GLP-1 drug semaglutide, better known by its brand name Ozempic, goes off-patent on 20 March 2026, after which more than 30 cheaper generic versions are expected to enter the Indian market.
What Triggered the Advisory
The CDSCO advisory is prompted by a wave of multimedia obesity awareness campaigns launched by major pharmaceutical companies that, while stopping short of directly naming or promoting their drugs, were building public awareness around obesity as a disease and encouraging people to consult doctors, a strategy widely understood in the industry as a way to generate demand for GLP-1 therapies without technically violating India's prohibition on direct-to-consumer drug advertising.
American pharmaceutical major Eli Lilly has been running a multimedia obesity awareness campaign since last year, including ad films featuring well-known actors Boman Irani, Ratna Pathak and Supriya Pathak to raise awareness of obesity as a disease and encourage doctor consultations.
Danish drug-maker Novo Nordisk recently ran a front-page advertisement in a leading national daily urging readers to consult doctors for obesity management. Neither campaign named a specific drug, but CDSCO has made clear it views such campaigns as surrogate promotion nonetheless.
"Any promotional activity, including so-called awareness campaigns that function as a surrogate advertisement for prescription-only drugs, shall be viewed seriously and may be treated as an irrational or misleading marketing practice," the advisory stated.
What the CDSCO Advisory Says
The advisory invokes the Drugs and Cosmetics Act, 1940 and the Drugs Rules, 1945, reminding all stakeholders that prescription drugs must be prescribed only by registered medical practitioners as per approved indications and conditions of marketing authorisation.
It identifies five categories of advertising, direct or indirect, that may attract regulatory action: promotion of prescription-only medicines to the public; exaggeration of therapeutic efficacy; suggestions of assured or guaranteed weight loss outcomes; downplaying of lifestyle modification measures such as diet, exercise, and behavioural interventions; and inducing demand for pharmacological therapy.
The prohibition is sweeping in its scope. It explicitly extends to 'any form of direct or indirect promotional activity in print, electronic, digital, social media, or any other public platform' and covers 'promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall or product visibility of the prescription product'.
All such activities, CDSCO warned, will be treated as violations.
Companies have also been directed to submit comprehensive risk management plans to ensure continued safety monitoring, and to ensure that prescribing information and patient information leaflets prominently display authorised personnel details and a dedicated consumer complaint mechanism.
A Market in Rapid Expansion
The regulatory crackdown comes against the backdrop of explosive growth in India's GLP-1 drug market. Sales in the injectable GLP-1 agonist segment, driven by new launches including Mounjaro, Wegovy, and Ozempic, rose 177% on a moving annual turnover basis to ₹1,446 crore in February 2026, compared with ₹571 crore in February 2025. The pace of growth reflects the global buzz around these drugs and the sheer scale of India's metabolic disease burden.
The numbers are stark. The World Health Organisation (WHO) estimates for FY23-24 put the number of Indians living with diabetes at around 101mn (million), with another 136mn in the pre-diabetes category. Studies suggest India has 254mn people with generalised obesity and 351mn with abdominal obesity, a disease burden that makes it one of the most attractive potential markets in the world for weight-loss therapies.
What GLP-1 Drugs Do
GLP-1 receptor agonists work by mimicking the glucagon-like peptide-1 hormone, which regulates blood sugar, increases the feeling of fullness, and slows stomach emptying resulting in weight loss and improved glucose control. They were originally developed and approved for type-2 diabetes management but have more recently gained regulatory approval in several markets for obesity treatment as well.
In India, Mounjaro and Ozempic are currently approved only for type-2 diabetes and prescriptions are restricted to diabetic patients. The awareness campaigns launched by Eli Lilly and Novo Nordisk are therefore aimed at building a broader public understanding of obesity as a treatable medical condition, in anticipation of expanded approvals and the post-patent generic wave, rather than promoting currently approved indications.
The Ozempic Patent Cliff
The timing of CDSCO advisory, nine days before Ozempic goes off-patent on 20th March, is unlikely to be coincidental. With more than 30 generic versions of semaglutide expected to enter the Indian market at significantly lower price points than the branded product, competition for market share is about to intensify sharply. In that environment, the temptation for companies to use awareness campaigns, celebrity endorsements and digital outreach to build brand recall and consumer demand ahead of the generic flood would have been considerable — and CDSCO appears to have acted pre-emptively to close that avenue.
The Regulator's Broader Message
Beyond the immediate prohibition, CDSCO used the advisory to make a broader public health point: obesity is a chronic metabolic condition that requires comprehensive management, including lifestyle interventions such as diet, exercise, and behavioural change. Pharmaceutical therapy, where indicated, must not be presented in a manner that undermines or sidelines those interventions.
"Obesity is a chronic metabolic condition requiring comprehensive management, including lifestyle interventions. Pharmaceutical therapy, where indicated, must not be projected in a manner that undermines public health initiatives promoting diet control, physical activity, and preventive healthcare measures," the advisory stated.
The regulator also flagged the risk to vulnerable populations, directing all companies to ensure that their marketing practices do not exploit those who may be susceptible to promises of easy weight loss through medication.
